YDES News

Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics.

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer detection powered by DNA methylation and multi-biomarkers, next-generation precision diagnostics and stem cell therapy & exosome platforms focused on ophthalmology conditions. With 1,500+ visitors and 541 on-site surveys in 4 days, this significant event served as a critical gateway for YD Bio to connect with key stakeholders, explore new market opportunities globally, and reinforce its position as an innovator in the world’s healthcare landscape, providing an unparalleled platform to engage with

(NASDAQ:YDES) Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW...

TAIWAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. (“Breeze”), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio’s ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols “YDES” and “YDESW,” respectively. The transaction was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025.